View Post

Mature Data Drive New Insights With Novel Agents in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Caroline Seymour From: onclive.com The data with CDK4/6 inhibitors, PI3K inhibitors, antibody-drug conjugates, and PARP inhibitors in metastatic breast cancer continue to support their use in the clinic. The data with CDK4/6 inhibitors, PI3K inhibitors, antibody-drug conjugates (ADCs), and PARP inhibitors in metastatic breast cancer continue to support their use in the clinic, explained Lisa A. Carey, MD, FASCO. …

View Post

Overcoming Mechanisms of Resistance to CDK4/6, PI3K Inhibition in Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Hayley Virgil From: onclive.com Cynthia X. Ma, MD, PhD, discusses several research efforts examining mechanisms of resistance to CDK4/6 and PI3K inhibitors in breast cancer and some of the novel combinations that may possess the potential to overcome this challenge. Although survival outcomes have improved for patients with metastatic estrogen receptor (ER)–positive breast cancer with the addition of CDK4/6 …

View Post

Expert Reviews Novel Strategies in the Pipeline for the Treatment of ER-Positive Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: Audrey Sternberg From: targetedonc.com Recent acceleration in the introduction of new regimens for the treatment of estrogen receptor (ER)–positive breast cancer has led to significant survival enhancement, but questions remain regarding how patients should be stratified following disease progression with these therapies.1 “In the last 7 or 8 years, we’ve seen the CDK4/6 inhibitors added to endocrine therapy and …

View Post

CDK4/6 Inhibitors Shift Standards in HR+ Metastatic Breast Cancer

In In The News by Barbara Jacoby

By: Erica DiNapoli From: onclive.com Most discussion in hormone receptor (HR)–positive metastatic breast cancer are now focused on CDK4/6 inhibition, according to Denise A. Yardley, MD, who added that, after demonstrating significant survival benefits, these agents have transformed the standard of care. “There are 3 key agents: palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio). Several phase 3 trials incorporating these …

View Post

CDK4/6 Inhibitors for Breast Cancer: Who Does, Doesn’t Benefit?

In Clinical Studies News by Barbara Jacoby

By: Nick Mulcahy From: medscape.com One of the success stories in recent years in the treatment of metastatic, hormone-receptor positive breast cancer has been the addition of drugs acting as inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6) on top of endocrine therapy. Three such drugs are now available — palbociclib (Ibrance, Pfizer), ribociclib (Kisqali, Novartis), and abemaciclib (Verzenio, Lilly). …

View Post

OS Benefit is Shown in CDK4/6 Inhibitors for Metastatic HR+ Breast Cancer

In Clinical Studies News by Barbara Jacoby

By: ELLIE LEICK From: oncnursingnews.com The recent readout of overall survival (OS) data with CDK4/6 inhibitors in patients with metastatic hormone receptor (HR)–positive, HER2-negative breast cancer has been unprecedented, according to Komal Jhaveri, MD, FACP. “With all of the newer targeted therapies that are currently approved, there has been a lot of exciting data presented in 2019 and 2018 for …

View Post

CDK4/6 Inhibitors for Metastatic Breast Cancer: What You Need to Know

In Clinical Studies News by Barbara Jacoby

By: BRIELLE BENYON From: oncnursingnews.com The advent of CDK4/6 inhibitors has caused landmark change in the treatment and outcomes of patients with metastatic hormone receptor (HR)-positive, HER2-negative breast cancer. Three agents were already on the market – palbociclib (Ibrance), ribociclib (Kisqali), and abemaciclib (Verzenio) – with a fourth, alpelisib (Piqray), approved this May. This could change the space even more …

View Post

Which Patients Should Get CDK4/6 Inhibitors?

In Clinical Studies News by Barbara Jacoby

Some, however, are asking instead: who should not get them? By: Kristin Jenkins From: medpagetoday.com The approval of three cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors for the treatment of patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2−) advanced breast cancer has completely changed the way in which oncologists view and manage up to 75% of invasive breast …